Aptevo Therapeutics is a biotech company based in Seattle, Washington, focused on revolutionizing cancer treatment through the development of novel immuno-oncology therapeutics. At the forefront of innovation, Aptevo pioneers the use of their proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies to create therapeutic candidates that aim to significantly improve outcomes for cancer patients. With an empowering work environment and an entrepreneurial culture, Aptevo attracts some of the most innovative minds in the industry.

Their pipeline boasts two clinical candidates and three preclinical candidates, all in development to advance cancer treatment and enhance patient outcomes. Aptevo's proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms offer a promising future for cancer treatment. These platforms not only provide numerous opportunities for partnering and licensing arrangements, but also reflect the company's core values of ownership and collaboration.

Aptevo's commitment to innovation, dedication, and development expertise places them at the forefront of immuno-oncology, shaping the science of what's next. To learn more about their management team, board of directors, or explore partnership opportunities, visit Aptevo Therapeutics' website